Recent Updates
Recently added Catalysts
TMO Positive Sentiment

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

Key Takeaway: Thermo Fisher Scientific announced the launch of Gibco™ VaxEvo™ CD 293 Medium, aimed at enhancing adenovirus vaccine production. This medium is chemically defined and animal origin-free, supporting suspension HEK293 cell growth. It is available in both liquid and AGT™ formats, catering to vaccine developers from early development through manufacturing.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of Gibco™ VaxEvo™ CD 293 Medium
  • Supports high-titer adenovirus production
  • Designed for vaccine developers
  • Available in liquid and AGT™ formats

Full Press Release Details

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the Gibco™ VaxEvo™ CD 293 Medium, a chemically defined and animal origin-free medium designed to support suspension HEK293 cell growth and high-titer adenovirus production. Available in liquid and AGT™ formats, the medium is designed to support vaccine developers from early process development through scale-up and manufacturing. As suspension-based HEK293 workflows evolve to support s

Frequently Asked Questions

What is Gibco™ VaxEvo™ CD 293 Medium?

It is a chemically defined, animal origin-free medium for adenovirus production.

Who can benefit from the VaxEvo™ CD 293 Medium?

Vaccine developers can use it from early development to manufacturing.

In what formats is the VaxEvo™ CD 293 Medium available?

It is available in liquid and AGT™ formats.

What type of cell growth does the medium support?

It supports suspension HEK293 cell growth.

Last updated: Nov 18, 2026